 JUPITER, FL ACCESSWIRE July 8, 2020 Dyadic International, Inc. Dyadic, we, us, our, or the Company DYAI, a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it has entered into new fully funded collaborations with two of the leading global animal health companies to demonstrate the C1 technology platform for expression and production of therapeutic proteins for companion and farm animal diseases. The regulatory pathway in animal health is much shorter with the cost of goods being a much more critical issue when compared to human vaccines and drugs. 